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Most cells physiologically release vesicles as way of intercellular communication. The so-
called Extracellular Vesicles (EVs) include exosomes, ectosomes, and apoptotic bodies,
which basically differ in their composition and subcellular origin. Specifically, EVs found in
urine reflect the state of the urinary system, from podocytes to renal-tubular cells, thus
making them an excellent source of samples for the study of kidney physiology and pathol-
ogy. Several groups have focused on defining biomarkers of kidney-related disorders, from
graft rejection to metabolic syndromes. So far, the lack of a standard protocol for EVs
isolation precludes the possibility of a proper comparison among the different biomarkers
proposed in the literature, stressing the need for validation of these biomarkers not only
in larger cohorts of patients but also considering the different methods for EVs isolation.
In this review, we aim to gather the current knowledge about EVs-related biomarkers in
kidney diseases, with a special emphasis in the methods used to date for EVs enrichment,
and discussing the need for more specific protocols of EV isolation in clinical practice.
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INTRODUCTION
Extracellular Vesicles (EVs) have awakened the interest of the
scientific community due to their different roles in intercellular
communication, pathogenesis, drug, and gene vector delivery, and
as possible reservoirs of biomarkers (1–3). These vesicles can be
released from different kind of cells, from platelets to cells of the
immune system and neurons, among others (4), and can be found
in several body fluids, including plasma, urine, and saliva (5, 6).
The term EVs includes different types of vesicles, mainly exo-
somes (EXs), ectosomes, and apoptotic bodies. These distinct
types of vesicles differ in several aspects (7, 8). EXs are 30–150 nm
diameter vesicles derived from the inward budding of endosomal
membranes, resulting in the progressive accumulation of intralu-
minal vesicles (known as EXs) within large multivesicular bodies
(MVBs). These EXs are released to the milieu by fusion with the
plasma membrane (8, 9). Ectosomes, also referred as Microvesicles
(MVs) are bigger than EXs (100–1000 nm) and they are produced
by the direct budding of the plasma membrane (10). Finally, dying
cells also shed membranous vesicles, called apoptotic blebs, with
heterogeneous shape and size (8). Hence, the different subcellular
origin of EVs accounts for their specific composition and function.
In this sense, EVs contain a specific subset of common proteins
related to biogenesis and trafficking and also a specific signature
from their cell or tissue of origin (8, 11), including protein and
nucleic acids (4, 12, 13). Therefore, the study of the proteome and
the nucleic acid content of EVs may provide information about
the cell or tissue of origin and, importantly, their physiological
state. Three public online databases including all gathered infor-
mation about EV content are available: EVpedia, ExoCarta, and
Vesiclepedia (2, 14–16).
Urine is a body waste fluid, which can be easily obtained, being
therefore an ideal fluid for biomarker determination and analysis.
But urine is a complex mixture of filtered and secreted proteins,
salts, urea, and metabolites that may vary, not only in physiological
situations but specially in diseases associated with renal involve-
ment (17, 18). In addition, the protein composition of the urine is
highly dependent on the glomerular filtration rate (GFR), tubular
metabolism, tubular reabsorption, diet, and hydration status of
the patient among others. The variation in the concentration of a
certain protein could be the result of any tissue disorder or patho-
physiological alteration. It is estimated that only around 3% of
urine proteins are contained in urinary EVs. Therefore, potential
interesting biomarkers contained in EVs may be just undetected
due to their dilution in whole urine. Thus, the determination of
biomarkers specifically related to urinary EVs may be of interest
to uncover alterations on the renal system (18).
ISOLATION TECHNIQUES AND METHODS TO OBTAIN
URINARY EXTRACELLULAR VESICLES
The complexity of body fluids, and in this case urine, hampers the
study of the specific molecular content of EVs.
A previous step to EVs isolation is the management of the sam-
ple. Based on the studies of Zhou et al. (19), which focused in
the protein content of EVs, it is recommended the use of protease
inhibitors in the collection containers to preserve the sample. In
addition, an extensive vortex is required to recover the highest
amount vesicles, as EVs could remain attached to the plastic. Sam-
ples can be either processed immediately or storage at−80°C. Due
to the lack of consensus in the published data, the international
society of EVs has recently published a position paper, in which
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they recommend further studies on this issue (6). In addition, as
a normal procedure in urine samples, bacterial contamination of
the physiologic micro-environment should be avoided (6, 20).
Many studies conducted to date have enriched urinary EVs
using methods that do not exclude the presence of non-EV conta-
minants. However, a gold-standard technique for isolating EVs in
the clinical practice is still missing. In this section, we summarize
and discuss the different methods used to isolate urinary EVs.
When initiating the isolation of urinary EVs, a first consid-
eration has to be paid to the presence of the Tamm–Horsfall
protein (THP)-also known as uromodulin-, a common compo-
nent of urine samples in both physiological and pathological
conditions. THP, among others proteins (such as albumin) that
are increased in urine under several kidney pathologies, do inter-
fere with urinary EVs-related biomarkers research and discov-
ery. Therefore, pre-isolation techniques to reduce or eliminate
their presence before any EVs isolation/determination are rec-
ommended (6, 21). DTT-treatment has been the most widely
solution to avoid EV-entrapment by THP (22). An alternative
to DTT is the use of 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonic (CHAPS), a mild detergent also proposed to
solubilize THP. The main advantage of CHAPS is the preservation
of the protein conformation and the enzymatic activity (23). This
may be important in experimental designs involving functional
activities of urinary EVs. However, it has been also mentioned that
CHAPS treatment is more time consuming than DTT-treatment
(24). Thus, the use of each method would be directed by the final
use of the sample.
Once these major contaminants are reduced, the sample is pre-
pared for enrichment and isolation of EVs. This could be achieved
following different methods.
ULTRACENTRIFUGATION
Ultracentrifugation was first used to isolate EVs by Jonhstone and
Stahl (25, 26), and since then it has been widely used for EVs iso-
lation regardless the origin of the sample. Thus far, most studies
found in the literature carry out a two-step differential ultracen-
trifugation (UC) to isolate EVs: a first low-speed centrifugation
at 10,000–17,000× g to eliminate cellular debris, apoptotic bod-
ies, and larger EVs, and a second step at higher speed – ranging
100,000–200,000× g depending on the study-, to pellet smaller
EVs. In some cases, this centrifugation method could be comple-
mented or replace with a size filtration step to remove protein
aggregates and cell debris. However, some authors consider that
filtration step may fracture larger EVs in smaller ones (6).
Under pathological conditions, when glomeruli filtration is
compromised, there is a massive loss of protein in urine. These
proteins, together with THP and their aggregates could be co-
isolated with urinary EVs. To obtain a more purified sample,
the pelleted EVs by the differential UC can be processed and
resolved by sucrose density gradients to remove contaminants
(27). Other density gradients such as potassium bromide or iodix-
anol (Optiprep™) have been recently proposed to isolate EVs
reducing protein contaminations in plasma (28, 29).
Although UC is the technique of reference for basic research in
EVs, major drawbacks undermine their applicability in the clinical
setting, including the high operator-dependent variability, the lack
of a universal protocol, the expensive equipment required, and the
low throughput (30).
FILTRATION
Filtration is based on passing the sample through a nanomem-
brane (in general polyethersulfone or PVDF membranes) in a
short low-speed centrifugation. This method avoids UC, and can
be used with low-volume samples. Cheruvanky et al. analyzed this
method as a new option for isolating urinary EVs. They detected
that some proteins classically related to EVs were retained by the
nanomembrane, thus making necessary an extra-washing step to
recover the total amount of EVs (31). In addition, Rood et al.
found a low recovery of EVs markers together with co-isolation of
proteins i.e., albumin within the urinary EVs pellet (21). Thus far,
the protein adherence to the nanomembrane and the high pro-
tein retention are important disadvantages for isolating urinary
EVs from proteinuric patients using this method. Other options,
such as filtration applying vacuum or ultrafiltration, which use a
low protein binding membrane, can be used to purify urinary EVs
from low-volume samples (32).
IMMUNO-AFFINITY AND PEPTIDE-BASED ISOLATION
Extracellular vesicles are characterized by the presence of several
surface proteins, such as the tetraspanin family. Taking advan-
tage of this proteins expression, several affinity-based methods
have been developed to isolate EVs. These methods use antibod-
ies (attached to magnetic beads or other supports) to specific EV
proteins (4, 33). Immuno-isolation of EVs still requires a low-
speed centrifugation step or magnetic techniques to concentrate
vesicles (6, 24).
Ghosh et al. proposed a method for isolating EVs using a syn-
thetic peptide with specific affinity for heat shock proteins, which
are described as EVs markers (16). Similar to antibodies, this tech-
nique takes advantage of the membrane proteins present on the
surface of EVs. The so-called Vn-96 peptide seems to be able to
capture EVs from plasma, urine, and cell culture supernatant (34).
Nevertheless, due the lack of unequivocally specific EVs pan-
markers, EVs obtained by these methods would render biased
samples depending on the antibody or peptide used (9).
AGGREGATING AGENTS
Several commercial precipitation reagents have been introduced in
the last few years. These reagents such as ExoQuick-TC™, Total EX
isolation reagent from Invitrogen™, Exospin™, and miRCURY™
EX isolation kit from cells, urine and CSF, among others, are based
on aggregating agents followed by a low-speed centrifugation. The
advantage of these methods is their easy application and faster per-
formance, with a huge applicability in diagnostic laboratories and
low operator variability (35, 36). On the other hand, their main
drawback is the co-isolation of a complex mixture of EVs together
with protein aggregates (37) that may interfere with further EV-
related marker determination and analyses. Thus, these methods
still require of specific pre-treatments to eliminate larger EVs and
aggregates (4, 6, 24, 29).
SIZE-EXCLUSION CHROMATOGRAPHY
In the last years, size-exclusion chromatography (SEC) has been
applied to fractionate complex biologic samples, such as urine and
Frontiers in Immunology | Inflammation January 2015 | Volume 6 | Article 6 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gámez-Valero et al. Urinary extracellular vesicles in kidney diseases
plasma, and isolate EVs excluding the main contaminants, such as
protein aggregates or lipoproteins usually co-isolated by UC. Rood
et al. used UC followed SEC to optimize the purity of the urinary
EVs. Importantly, this group demonstrated that non-EV-related
contaminants could mask the presence of relevant EV markers
(21), thus emphasizing the importance of eliminating as much
contaminants as possible.
More recently, Muller et al. used this technique for isolat-
ing morphologically intact EXs without protein contamination
from human plasma samples (38, 39). In our laboratory, we have
obtained similar results using urine samples. Thus, SEC can be
applied to highly enrich EVs in an efficient manner. In addi-
tion, SEC is a medium throughput technique susceptible to be
implemented in the clinical setting.
MICROFLUIDIC-BASED METHODS
Microfluidic-based methods have been recently developed to iso-
late EVs. Exochip™ is a microfluidic-based platform based on
a polydimethylsiloxane matrix covered with Abs against CD63
(classical exosomal marker) developed for the immuno-affinity
isolation of circulating EVs. This method does not require a sep-
aration step for quantification of EVs, as the vesicles are labeled
with a fluorescent dye allowing their quantification using a plate
reader. In addition, RNA extraction or proteomic studies can be
carried out as well (40).
Recently, Santana et al. have developed a microfluidic platform
to isolate EVs based on their diameter and the deterministic lateral
displacement. First assays carried out have shown an efficient sep-
aration among EVs subpopulations without altering their biology
and morphology. However, the ability to separate EVs aggregates
should be deeply analyzed in further experiments. In addition, this
technology should also be tested on complex biological samples in
which the density of the sample is highly variable (41).
HYDROSTATIC DIALYSIS
Musante et al. have recently presented hydrostatic dialysis to iso-
late urinary EVs without need of UC and as a possible solution to
highly diluted samples. This method is based in a dialysis mem-
brane with molecular weight cut-off of 1000 kDa, removing all
possible contaminants from EVs samples (36).
In summary, although different isolation methods for EVs have
been developed, a standard consensus – with special relevance in
the clinical settings – is still missing. This is of special importance
due to the variable results obtained when comparing different
techniques (37) or even when using different RNA extraction
methods, in which the presence of high amounts of RNA could be
indicative of non-EV contaminating RNAs (42).
URINARY EVs AS A SOURCE OF BIOMARKERS FOR
KIDNEY-RELATED DISEASES
Chronic kidney diseases are a public health issue as they cause
important morbidity and mortality and impose high economic
burden. Several studies suggested that the chronic kidney dis-
eases (CKD) are an independent predictor of mortality risk in
the general population (43). In addition, associations between
reduced GFR and the risk of death, cardiovascular events, and
hospitalization were observed (44).
The replacement therapy for patients with irreversible chronic
kidney failure includes hemodialysis or peritoneal dialysis, being
the renal transplantation (RTx) by far the modality of choice
for those patients (45). Many factors can affect long time graft
survival, and despite remarkable progress has been made in the
last years, immunologic rejection and adverse effects of immuno-
suppressive agents still have significant negative long-term conse-
quences.
Currently, kidney function is indirectly monitored by measur-
ing the GFR, creatinine clearance, serum creatinine, and protein-
uria. However, these markers are usually a late sign of kidney
damage that indicates – rather than predicts – renal dysfunction.
Moreover, the unique gold-standard technique to diagnose kidney
diseases is renal biopsy. Needless to say that needle biopsies are
an invasive non-reproducible technique, and may be associated
with patient morbidity. Thus, there is an additional need to find
non-invasive alternatives to kidney biopsies.
In the case of kidney failure and/or renal diseases, urine is the
perfect source of biomarkers for developing new diagnostic tools
to identify and stratify patients. Different research programs have
been conducted to biomarkers discovery. Initially, efforts were
focused to the analyses of total urine, while lately, the study of
urine derived EVs have gained interest. Particularly, urinary EVs
are secreted from all cell types that face the urinary space (glomeru-
lar structures, renal tubule cells, and the cells lining the urinary
tract) as represented in Figure 1. It is thus considered that urinary
EVs may be a non-invasive image of the physiological state of the
renal-tubular system (18, 46). Therefore, an increasing amount of
research groups have focused their interest in the study of urinary
EVs in kidney diseases. To date, several proteomic studies on EVs
have identified proteins that could be associated to kidney diseases
(47, 48). Table 1 shows a summary of the current state of biomark-
ers discovery related to kidney disorders, which are also detailed
below.
ACUTE KIDNEY INJURY
Acute kidney injury is a disorder characterized by a rapid decline
in the GFR and retention of nitrogenous waste products (71).
Acute kidney injury can be divided in: pre-renal, intrinsic, and
post-renal. Pre-renal acute kidney injury (AKI) is the most com-
mon cause of AKI and is an appropriate physiologic response to
renal hypo-perfusion. The causes of intrinsic acute renal failure
(ARF) can be categorized into the following: diseases involving
large vessels, diseases of renal microvasculature and glomeruli,
ischemic, and nephrotoxic acute tubular necrosis, all processes
involving tubulointerstium. Post-renal AKI is due to urinary tract
obstruction and accounts for<5% of cases of AKI (72).
Acute kidney injury may be one of the best examples in which
serum creatinine concentration (Scr) is used as biomarker of kid-
ney failure. Nonetheless, its concentrations vary widely, and it is
not informative in asymptomatic stages and cannot predict the
outcome of the disease. It is known that substantial loss of GFR
may not manifest with elevations in Scr for several days, and
creatinine based estimated GFR is not accurate.
Serum creatinine concentration concentration increases when
renal filtration is decreased at least 30%. Moreover, it has been
shown that high levels of Scr may not be associated to renal-tubular
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FIGURE 1 | Schematic representation of potential urinary EVs
biomarkers from the urinary tract. Potential biomarkers identified in
urinary EVs from different regions of the nephron, renal tubule, and the
bladder. Mentioned molecules are hypothetically related to a specific
region of the renal system. Podocyte: LGALS1: lectin galactoside-binding
soluble 1; HSPG2 heparan sulfate proteoglycan 2. Distal convoluted
tubule: SLC2A3: solute carrier family 2; NCC: Na-Cl co-transporter;
Proximal convoluted tubule: AQP-1: Aquaporin-1; CA4: carbonic anhydrase
4; CLCNS: chloride channels; SLCA3: solute carrier family 3; MME:
membrane metallo-endopeptidas; Loop of Henle: UM: uromodulin;
bDKRB1: bradykinin receptor B1; CALCR: calcitonin receptor; SLC2A1:
solute carrier family 2; NKCC: Na+/K+/2Cl− co-transporter; Collecting tube:
AQP2: aquaporin-2; ATP6V1B1: TPase, H transporting, lysosomal 56/58 kD,
V1 subunit B; SLC12A1: Sodium potassium chloride co-transporter 2;
Bladder: LASS2: ceramide synthase 2; GALNT1 polypeptide
N-acetylgalactosaminyltransferase 1.
injury or kidney injury (73). These reasons clearly reflect the need
for new more sensitive biomarkers.
Kidney injury molecule-1, neutrophil gelatinase-associated
lipocalin (NGAL), or interleukin-18 have been proposed as poten-
tial biomarkers for the early diagnosis of AKI in total urine
(4, 74). Besides, other groups have recently reported Heat Sock
Protein 72 (Hsp72) as putative biomarker, demonstrating an
increase in mRNA levels after ischemia and kidney injury (73,
75). Despite these new approaches in biomarkers research, the
“classical” parameters already mentioned continue to be used.
As mentioned before, one of the possible causes of acute renal
damage is renal ischemia-reperfusion. During the ischemia, the
absence of nutrients and oxygen creates a hypoxic condition,which
promotes the reactive oxidative species formation and inflamma-
tory response once the blood flux is restored. Related to EVs, Zhou
et al. identified EVs containing Fenituin-A as potential biomarker
after renal injury using an AKI rat model. These EVs were detected
not only before any increase in Scr levels but also before any struc-
tural change could be detected by kidney biopsy. In addition, this
marker was in the same way detected in total urine (76). A few years
later, the same group identified transcription factor 3 (ATF3) as an
additional EVs biomarker for AKI. Importantly, these biomarkers
were only detected on EVs coming from patients and were not
present in healthy volunteers (49).
Also, in a rat model for ischemia-reperfusion, Sonoda et al.
reported the decrease of exosomal aquaporin-1. Similar results
were confirmed in a transplant group of patients (50). The most
interesting feature of this biomarker is that they could not find this
decrease in EVs in a rat model of nephrotic syndrome, suggesting
that this marker could be specific for this pathological state.
GLOMERULAR DISEASES
Podocytes are specialized epithelial cells forming the glomerular
filtration barrier together with the glomerular basement mem-
brane and endothelial cells. The damage of this structure leads to
a loss of proteins and blood cells (77). In glomerular diseases,
podocytes are the main cells affected being therefore consid-
ered, which podocyte-derived EVs may be a promising source of
biomarkers.
Diabetic nephropathy
One of the main causes of glomerular disorders is diabetic
nephropathy. Related to it, Barutta et al. described a differen-
tial expression of 22 exosomal miRNAs between normo and
micro-albuminuric patients. Interestingly, the levels of miR-145
and miR-130a in urinary EVs were increased in diabetic and
micro-albuminuric patients compared to normo-albuminuric
controls. In contrast, miR-155 and miR-424 levels were lower
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Table 1 | Summary of EVs biomarkers related to kidney disease.
Pathology Sample Isolation method Biomarker Reference Model
ACUTE INJURE
AKI Spot DC/200000g Fetuin A (76) Rat and human
10–16 ml DC/200000g ATF3 (49) Rat and human
I/R 5–8 ml DC/200000g Aquaporin-1 (50) Rat and human
10–16 ml DC/200000g Transcription factor 3 (49) Rat and human
GLOMERULAR INJURY
FSGS 10–16 ml DC/200000g Wilm’s tumor 1 (49, 51) Rat and human
45 ml DC/200000g+SEC PODXL (21) Human
GKD 15 ml DC ADAM10 (52) Cell line and human
DN 450 ml DC/200000g miR-130, miR-145, miR-155, and miR-424 (53) Mice, cell line, and human
– Filtra-centrifugation DPP IV (54) Human
100 ml DC/175000g AMBP, MLL3, and VDAC1 (55) Human
LN – DC/200000g miR-26a, ADAM10 (56) Mice and human
IgAN 30 ml SGC Ceruloplasmin and miR-26a (57) Human
TBN 30 ml SGC Aminopeptidase A and vasorin
FIBROSIS
RF – DC/2000000 miR-29c and miR-200 (58) Human
GF – DC/200000g CD2AP, synaptodin mRNA (59) Human
OTHER RENAL DISORDERS
CKD 25 ml Ultrafiltration mRNA Il-18, NGAL (60) Human
Tx 10 ml DC/200000g NGAL (61) Human
200 ml DC/100000g CD133 (62) Human
PKD – DC/150000g PKD1, PKD2, PKHD1 (63) Human
CANCER
MPC 5 ml DC/100000g ATGB1 (64) Cell line and human
ITGA3 Cell line and human
– DC/110000g miR-34a (65) Cell line and human
200 ml DC/100000g PSA, PSMA (66) Cell line and human
BC – SGC EDIL-3 (67) Cell line and human
– DC/100000g LASS2, GALNT1 (68) Human
50 ml DC/100000g TACSTD2 (69) Human
RCC 50 ml DC/200000g MMP-9, DKP4, EMMPRIN, PODXL (70) Human
Methods: DC, differential centrifugation; SGC, sucrose gradient centrifugation.
Disease: AKI, acute kidney injury; I/R, isquemia reperfusion injury; FSGS, focal segmentary glomerulosclerosis; GKD, glomerural kidney disease; DN, diabetic nephropa-
thy; LN, lupus nephritis; IgAN, IgA nephropathy; TBN, thin basement nephropathy; RF, renal fibrosis; GF, glomerulofibrosis; CKD, chronic kidney disease; RTx, renal
transplantation; PKD, polycystic kidney disease; MPC, metastatic prostate cancer; BC, bladder cancer; RCC, renal cell cancer.
Biomarkers: PODXL, podocalyxin-like; AMBP, α-microglobulin/bikunin precursor; MLL3, histone-lysine N-methyltransferase;VDAC1, voltage-dependent anion-selective
channel protein 1; CD2AP, CD2-associated protein; NGAL, neutrophile gelatinase-associated lipocalin; ATGB1, GTP-binding protein 1; ITGA3, integrin, alpha 3;
PSA, prostate specific antigen; PSMA, prostate specific membrane antigen; EDIL-3, EGF-like repeats and discoidin I-like domain-; LASS2, ceramide synthase 2;
GALNT1 polypeptide N-acetylgalactosaminyltransferase 1; MMP-9, matrix metalloproteinase 9; DKP4, Dickkopf related protein 4; EMMPRIN, extracellular matrix
metalloproteinase inducer; PKD1, polycystin-1; PKD2, polycystin-2; and PKHD, 1 polyductin.
in micro-albuminuric patients whilst normo-albuminuric and
healthy controls showed similar levels (53). Then, in mesangial
cells cultures, they demonstrated that hyperglycemic conditions
induce miR-145 expression. Thus, this miRNA profile represents a
novel approach in the search of EVs biomarkers, although further
studies with larger cohort of patients are required.
Another interesting putative biomarker for diabetic nephropa-
thy is dipeptidyl-peptidase. This enzyme, which plays a role in
T-cell activation, is known to be over-expressed in the plasma
of diabetic patients. Its high expression in the kidney took Sun
et al. to analyze the vesicular content in a subset of patients and
found over-expression of this protein in urinary EVs compared to
controls (54).
The quantitative analysis of urinary EVs proteome from dia-
betic patients carried out by Zubiri et al. showed interest-
ing differences compared to controls. Interestingly, 65% of the
proteins detected were identified only in one of the experi-
mental groups. Among those, α-microglobulin/bikunin precur-
sor (AMBP), histone-lysine N-methyltransferase (MLL3) were
increased in patients, whilst voltage-dependent anion-selective
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channel protein 1 (VDAC1) were decreased (55). Hence, these
proteins are suggested as promising biomarkers, although more
studies are needed for verification.
Glomerulonephritis
IgA nephropathy is the most common glomerular lesion of
glomerulonephritis whose clinical presentation may vary from
hematuria to rapidly progressive glomerulonephritis. Specifi-
cally, IgA nephropathy (IgAN) is induced by: aberrant glycosy-
lation of IgA1, synthesis of antibodies directed against galactose-
deficient IgA1, binding of the galactose-deficient IgA1 by the anti-
glycan/glycopeptide antibodies to form immune complexes and
accumulation of these complexes in the glomerular mesangium.
Moreover, each step of this pathological process has suscepti-
bility locis proposed by genome-wide association studies but
DNA-based test have not been developed (78).
Purification of urinary EVs from IgA nephropathy patients
was carried out by Moon et al. (57). These authors identified
ceruloplasmin (CP) as biomarker in this disease. In this way,
CP concentration appeared higher in IgA patients than in con-
trols; though deepest studies must be perform to confirm these
results.
Another important glomerulopathy characterized by podocyte
injury is the focal segmental glomerulosclerosis. This pathology
could be autoimmune or secondary to obesity and drugs among
others. Initial studies by Zhou et al. (49) demonstrated the over-
expression of the Wilm’s Tumor 1 protein, a transcription factor
required for normal kidney development, in urinary EVs from a
mice model with podocyte injury and in humans with focal seg-
mental glomerulosclerosis (49). Some years later, the results were
re-evaluated and confirmed by the same group in a larger cohort
of patients (51).
Lupus nephritis is a frequent and potentially serious complica-
tion among patient with systemic lupus erythematosus whose clin-
ical manifestations are varied being the most common manifes-
tations proteinuria (commonly leading to nephrotic syndrome),
microscopic hematuria, and reduced GFR. The histopathology of
lupus nephritis (LN) is pleomorphic; based on light microscopic
(LM), immunofluorescence (IF), and electron microscopic (EM)
findings it can be classified into six classes (79).
Some differences in the levels of several miRNAs have been
reported between controls and LN and IgAN patients. Among
those, miR-26a is normally found in the glomeruli of control sam-
ples, but their levels are decreased in glomeruli from patients.
Interestingly, Ichii et al. (56) have reported a higher level of
miR-26a in EVs from patients compared to controls, thus sug-
gesting a mechanism for the reduced levels found in patient’s
glomeruli. The authors suggested this microRNA could be consid-
ered a direct and predictive biomarker of podocyte and glomerular
injury.
Similarly, Gutwein et al. studied ADAM10 and its substrate
L1, are expressed in differentiated podocytes. Moreover, ADAM10
could be found in urinary EVs and in total urine of LN and IgAN
patients but it is absent on healthy donor urine or EVs (52).
Although it is not clear the role of this molecule in the kidney
or in the EVs, their differential expression suggests they could be
considered as possible biomarkers of glomerular damage.
Thin basement membrane nephropathy
Thin basement membrane nephropathy is characterized by
non-progressive hematuria, minimal proteinuria, and normal
renal function due to a thinned glomerular basement membrane.
This pathology is thought to be caused by mutation in collagen
genes such as COL4 and COL5 (80).
Renal biopsy is the only technique to diagnose between IgAN
and thin basement membrane nephropathy (TBMN). In urinary
EXs from TBMN patients’, aminopeptidase N, and vasorine pre-
cursors were increased compared with IgAN patients. Thus, these
precursors could be used as biomarkers in hematuric patients to
differentiate between TBMN and early IgAN (57).
KIDNEY FIBROSIS
As mentioned before, CKD is a major death cause worldwide,
associated with fibrosis leading to organ failure in the final stages,
independently of the primary cause. Lv et al. (58) found a reduced
level of urinary EVs miR-29 and miR-200 in a selected group
of CKD patients compared to controls. Furthermore, they found
that miR-9a and miR-29c could discriminate between mild and
moderate-severe fibrosis. Similarly, the same group evaluated
other molecules such as CD2AP, NPHS2, and synaptodin mRNA
in urinary EVs. They reported an increase of synaptodin and
a decrease in CD2AP mRNA levels in patients. As before, their
results suggested that CD2AP mRNA levels could reflect tubule-
interstitial fibrosis and the glomerulosclerosis degree (59). These
results clearly support the idea of using RNA content from uri-
nary EVs as non-invasive tools in the study of renal function and
diseases progression.
POLYCYSTIC KIDNEY DISEASE
Polycystic kidney disease (PKD) is a genetic disorder characterized
by kidney cystic dilatations that may course with multiple organ
involvement. This disease is caused by a dysregulation of PKD1,
PKD2, or PKHD1 genes (81, 82). Proteomic studies in urinary
EVs by several groups revealed that polycystin-1, polycystin-2, and
polyductin (products of the mentioned genes) are easily detectable
in patients’ samples, and therefore could be considered for the
analysis of the disease (18, 63).
RENAL TRANSPLANTATION
Renal transplantation is the best option for end stage renal disease
patients.
The use of urinary EVs as a source of biomarkers for kid-
ney injury after RTx was probed by Alvarez et al. (61). In this
study, the authors demonstrated the presence of NGAL in cellu-
lar fraction and in urinary EVs from patients. Urinary EVs NGAL
detection differed between patients and controls. Interestingly, dif-
ferent quantities of NGAL were detected between deceased and
living donors. Thus, suggesting that NGAL could be a biomarker
of damage and delayed graft function (61).
Likewise, it has been recently published that other proteins
classically associated to kidney injury in total urine could not be
considered as EV biomarkers such as kidney injury molecule-1
(KIM-1) and cystatin. These molecules did not shown significant
changes in urinary EVs while NGAL mRNA was decreased after
transplantation but arose to normal levels in a few days (60); in
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addition, EV NGAL did not correlate with creatinine reduction.
Moreover, in this case, urinary levels of IL-18 and NGAL correlate
better with creatinine reduction than EVs markers (60). NGAL,
KIM-1, and IL-18 have been proposed as AKI biomarkers as well,
but it seems that in the case of RTx, these EVs markers do not corre-
late with outcome or creatinine level. Thus, the patients’ selection,
the degree of the disease and the biomarkers approach play a crit-
ical role in the wide of results found between studies. One of the
main goals in the search of urinary EVs biomarkers is the repro-
ducibility of the results between different methods and different
sample volumes, among others.
The presence of urinary EVs expressing the progenitor marker
CD133 has been lately reported by Dimuccio et al. (62). In healthy
donors, they could identify two EVs subpopulations based on
CD133 expression with a different profile for classical and uri-
nary specific markers. These CD133+ EVs were detectable at high
levels in urine from healthy donors but not in patients with end
stage renal disease. In the case of transplanted patients, CD133+
EVs levels were lower than in healthy donors but higher than in
chronic patients. The authors considered CD133+ EVs as possible
biomarkers for tubular function and renal tissue regeneration after
transplantation in order to detect possible graft rejection, kidney
damage, or incomplete tissue regeneration.
RENAL CELL CARCINOMA
Recently, the comparison of the protein profile of urinary EVs
derived from renal cell carcinoma (RCC) patients with control
subjects was carried out by Raimondo et al. (70). This study
has shown a different protein profile between them. Specifi-
cally, in the case of matrix metalloproteinase 9 (MMP-9), Dick-
kopf related protein 4 and Extracellular Matrix Metalloproteinase
Inducer (EMMPRIN), all of them involved in matrix remodeling,
and found over-expressed in RCC patients. Moreover, these pro-
teins correlated with the disease progression and the metastatic
potential (70).
PROSTATE CANCER
Benign prostate hyperplasia is one of the most common diseases in
men, and only a low proportion of prostate hyperplasias progress
to an aggressive disease. The current diagnostic protocol of this
tumor includes the serum determination of the prostate spe-
cific antigen (PSA), digital rectal examination, and biopsy. This
combination could fail identifying properly between aggressive or
non-aggressive cancer, leading to an over-treatment of patients
(83). Despite urine would be apparently the best biological fluid
to find new biomarkers in this pathology, a major effort has
been focused in plasma samples (84). Regarding to urine stud-
ies, Mitchell et al. found the presence of prostate markers PSA
and PSMA in EVs from patients’ samples compared to EV’s from
healthy controls (66). Recently, ITGA3 and ITGB1 proteins have
been identified significantly more abundant in urinary EVs from
metastatic prostate cancer patients compared to benign prostate
hyperplasia patients and patients without metastasis (64).
Corcoran et al. (65) described a panel of miRNAs that could
be used as biomarker for metastatic prostatic cancer. This panel
was set up from studies performed in cell lines in previous pub-
lications, and analyzed in human urine samples. The decreased
expression of miR-34a is suggested to be a useful tool to discrimi-
nate between prostate cancer and benign hyperplasia. In addition,
BCL-2, a well-known pro-apoptotic gene, is described as the target
of this miRNA (65).
BLADDER CANCER
Together with prostate and RCC, bladder cancer is another impor-
tant disorder of the urinary tract. Recently, it was described that
urinary EVs from bladder cancer patients promote tube forma-
tion on endothelial cell lines and cell migration; once again EVs
are shown to be a vehicle to promote cancer progression. Chen
et al. reported the diagnostic potential of the cancer-related pro-
tein TACSTD2 in a short cohort of bladder cancer patients (69).
Moreover, EGF-like repeats and discoidin I-like domain-3 (EDIL-
3) was found to be over-expressed on bladder cancer cell lines
(67). Later, the presence of this protein was confirmed in patients’
EVs (67).
Recently, Perez et al. described a different expression pro-
file for four different EV mRNA encoding for LASS2, GALNT1
ARHGEF39, and FOXO3 (68). Briefly,ARHGE39 and FOXO3 were
detected only in controls whilst GALNT1 and LASS2 were detected
only in urinary EVs from patients. Further studies are required to
assess these proteins as bladder cancer biomarkers.
EVs AS A THERAPEUTIC APPROACH IN KIDNEY DISEASES
Research on EVs is not only focused on their potential role as
source of biomarkers but also as new therapeutic tools. Taking
into account the properties and functions of EVs, different clin-
ical studies have been developed with the aim to use them in
therapy (85).
In the context of AKI, only a few studies have tested differ-
ent sources of EVs for their therapeutic potential. Cantaluppi
et al. tested the effect of EVs from endothelial progenitor cells
in a rat model for ischemia and reperfusion injury. The miRNA
content of these vesicles seems to have a positive effect in tubu-
lar cells, reducing apoptosis and promoting cell proliferation (86,
87). Ischemia-reperfusion is characterized by the over-expression
of the adhesion molecule MCP-1. During this process, transcrip-
tional repressor activating transcription factor 3 (ATF3), which has
an anti-apoptotic effect and inhibit inflammatory state, is induced.
Chen and colleagues probed that injection of exosomal ATF3 into
model mice, reduces I/R kidney injury (88). Similarly, the effect
of liver stem cells EVs in the regeneration of renal tubule injury
has been demonstrated in the last months. Sánchez et al. suggest
the role of these vesicles in a paracrine mechanism, inhibiting
apoptosis of renal-tubular cells in an AKI murine model (89).
CONCLUSION
Kidney-related diseases, among others, might clearly benefit of
research focused on urinary EVs. These vesicles may concentrate
potential biomarkers – otherwise unnoticed by dilution in whole
urine – that may reflect the physiological state of the renal system,
and which may be relevant in several pathologies affecting the uri-
nary tract, from the kidney to the bladder. However, some issues
need to be solved before urinary EVs could be established as a
source of biomarkers in the clinical setting. First, it is important to
define whether these potential biomarkers should be determined
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in whole urine or specifically associated to urinary EVs, as this
could be related to each pathologic condition. It is considered that
RNA and proteins are better preserved in EVs than in urine, being
protected from the milieu. Indeed, EVs have the advantage of being
directly derived from cells of the renal system, but the disadvan-
tage of needing additional steps. Moreover, due to the different EV
isolation procedures used – perhaps biasing the results – it is not
clear whether some of the biomarkers identified so far are actually
EV-related. Thus, a standard consensus on this subject would be
desirable before blind studies on larger cohort of patients are per-
formed to unequivocally identify urinary EV-related biomarkers
for kidney diseases. Although most of the results so far are still
preliminary, several of the proposed biomarkers have enlighten
the way to a better understanding and diagnose of kidney diseases.
Besides, as EVs can target and modify the behavior of specific
cells, their potential use in therapeutic protocols will merit future
research in kidney-related diseases.
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